Loading…

First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy

To simplify surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy (HOCM), we developed a novel transapical beating-heart septal myectomy (TA-BSM) procedure. In this study, we sought to evaluate the clinical utility of TA-BSM in a first-in-human trial. Patients with HOCM were...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2023-08, Vol.82 (7), p.575-586
Main Authors: Fang, Jing, Liu, Yani, Zhu, Ying, Li, Rui, Wang, Rui, Wang, Dao Wen, Song, Yunhu, Li, Chenhe, Chen, Yue, Cheng, Lin, Zheng, Kangchao, Zhao, Yun, Li, Shiliang, Cheng, Cai, Xia, Liming, Chen, Xiaoping, Wan, Song, Wei, Xiang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To simplify surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy (HOCM), we developed a novel transapical beating-heart septal myectomy (TA-BSM) procedure. In this study, we sought to evaluate the clinical utility of TA-BSM in a first-in-human trial. Patients with HOCM were enrolled if they presented with drug-refractory disabling symptoms. TA-BSM was performed via minithoracotomy with the use of our beating-heart myectomy device under echocardiographic guidance, without the use of cardiopulmonary bypass. Repeated resections were performed to tailor the extent of the septal myectomy for sufficient abolishment of left ventricular outflow tract (LVOT) obstruction and mitral regurgitation (MR). The primary outcome measure was procedural success, defined by resting/provoked LVOT gradient 
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2023.05.052